J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM
Kedudukan dalam Saham
#3899
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai,... J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
Harga Saham
$26.58
Disegerakkan terakhir: 2026-07-23
Modal Pasaran
$4.24B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
38.40%
Negara
IN
Perdagangan J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Kategori
Healthcare
Hasil untuk J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM)
Hasil pada Mar 2026 TTM: $457.75M
Menurut laporan kewangan terkini daripada J. B. Chemicals & Pharmaceuticals Limited, hasil semasa syarikat (TTM) ialah $457.75M. Pada tahun 2024, syarikat memperoleh hasil sebanyak $417.85M peningkatan berbanding hasil pada tahun 2023 iaitu $379.23M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi J. B. Chemicals & Pharmaceuticals Limited dari 2005 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $457.75M | -0.08% |
| 2025 | $458.10M | 9.63% |
| 2024 | $417.85M | 10.19% |
| 2023 | $379.23M | 18.75% |
| 2022 | $319.36M | 16.55% |
| 2021 | $274.01M | 18.45% |
| 2020 | $231.33M | -0.24% |
| 2019 | $231.89M | 9.00% |
| 2018 | $212.73M | 5.28% |
| 2017 | $202.07M | 14.60% |
| 2016 | $176.33M | 4.91% |
| 2015 | $168.07M | 7.33% |
| 2014 | $156.59M | 8.27% |
| 2013 | $144.63M | -8.54% |
| 2012 | $158.14M | -16.27% |
| 2011 | $188.85M | 14.47% |
| 2010 | $164.98M | 16.80% |
| 2009 | $141.25M | 0.50% |
| 2008 | $140.54M | 15.92% |
| 2007 | $121.24M | 15.95% |
| 2006 | $104.56M | 27.21% |
| 2005 | $82.19M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 1,344.40% |
IN
|
